Understand the source comparison
NAD+ vs SS-31: Which Is Better? — Real Peptides
A 2019 study published in Cell Metabolism found that age-related NAD+ depletion correlates with a 50% reduction in mitochondrial function by age 60. But supplementing NAD+ precursors only partially restores that capacity. SS-31 (Elamipretide), a mitochondria-t
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- A 2019 study published in Cell Metabolism found that age-related NAD+ depletion correlates with a 50% reduction in mitochondrial function by age 60. But supplementing NAD+ precursors only partially restores that capacity. SS-31 (Elamipretide), a mitochondria-targeting peptide, operates through a completely different mechanism: it binds directly to cardiolipin on the inner mitochondrial membrane, preventing oxidative damage before the energy production machinery fails. The difference matters because NAD+ addresses the symptom (energy depletion), while SS-31 targets the structural vulnerability that causes the depletion in the first place.
- Our team has worked with research institutions comparing these compounds across aging models, neurodegeneration protocols, and metabolic dysfunction studies. The decision between NAD+ and SS-31 isn't about which is 'better'. It's about matching the mechanism to the research question.
- What's the difference between NAD+ and SS-31 for mitochondrial health?
- NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular respiration and ATP production, declining 50% between ages 40–60. SS-31 (D-Arg-Dmt-Lys-Phe-NH₂) is a synthetic tetrapeptide that stabilizes cardiolipin, the phospholipid anchoring electron transport chain complexes to the inner mitochondrial membrane. NAD+ replenishes depleted energy substrates; SS-31 prevents membrane destabilization that triggers the energy crisis. They operate at different intervention points in mitochondrial decline.
- The comparison isn't one-to-one. NAD+ boosting (via NMN, NR, or direct NAD+ administration) restores substrate availability for sirtuins and PARP enzymes, supporting DNA repair and metabolic regulation. SS-31 doesn't affect NAD+ levels. It preserves mitochondrial cristae structure, preventing cytochrome c release and reducing reactive oxygen species (ROS) generation at Complex I and III. Research models targeting neurodegeneration often combine both: NAD+ to restore bioenergetic capacity, SS-31 to prevent the oxidative membrane damage that NAD+ supplementation alone doesn't address. This article covers the distinct mechanisms each compound targets, what the clinical and preclinical evidence shows, and how research teams decide which to deploy based on the pathology being studied.